Danish diabetes care giant Novo Nordisk's (NOV: N) has been impacted by supply chain issues, for the production of semaglutide, the active ingredient of its obesity drug Wegovy, as well as diabetes drugs Ozempic and Rybelsus. However, the company recently assured that US supplies were back on track, and this month it was revealed that Wegovy would be available on high-street pharmacies in the ... - The Pharma Letter